Clark G M, McGuire W L
Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio.
Semin Oncol. 1988 Apr;15(2 Suppl 1):20-5.
A review and update of published studies on prognostic factors support the following conclusions: The number of axillary lymph nodes involved with tumor remains the most important prognostic factor for women with primary breast cancer. In stage I disease, the lack of estrogen receptor (ER) seems to be the most important factor for predicting earlier recurrence and poorer survival. In stage II breast cancer, progesterone receptor (PgR) content appears to be better than ER content in predicting disease-free and overall survival. Measurement of proliferative activity (S-phase DNA) by thymidine labeling or flow cytometry (FCM) and of aneuploidy by FCM also provides prognostic information. Patients with aneuploid tumors, or with high S-phase diploid tumors, are at increased risk for relapse. Amplification of oncogenes, particularly HER-2/neu, may provide additional prognostic information in combination with other established prognostic factors.
受累腋窝淋巴结的数量仍然是原发性乳腺癌女性最重要的预后因素。在Ⅰ期疾病中,缺乏雌激素受体(ER)似乎是预测早期复发和较差生存率的最重要因素。在Ⅱ期乳腺癌中,孕激素受体(PgR)含量在预测无病生存期和总生存期方面似乎优于ER含量。通过胸腺嘧啶核苷标记或流式细胞术(FCM)测量增殖活性(S期DNA)以及通过FCM测量非整倍体也能提供预后信息。患有非整倍体肿瘤或高S期二倍体肿瘤的患者复发风险增加。癌基因的扩增,尤其是HER-2/neu,与其他已确立的预后因素相结合可能提供额外的预后信息。